Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy in Neoadjuvant TNBC After HIFU
NCT05491694Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological Complete Response at 6 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05491694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491694.